Canadian Budget Does Not Go Far Enough
CGPA Welcomes Investment But Calls For A More Comprehensive Strategy
While a promised investment in the life sciences sector included in the latest Canadian federal budget has been welcomed by the local off-patent industry, it says a “more comprehensive approach” is needed.
You may also be interested in...
In a new “blueprint” document, the CGPA has called for investment in Canada’s domestic generic pharmaceutical infrastructure to bolster its manufacturing and supply capabilities, as well as urging an enhanced international role and a local stockpile of essential drugs.
Celltrion has struck a deal with 180 Life Sciences to supply anti-TNF products to support the company’s work in pursuing new indications for off-patent biologics.
Stada has struck a deal to partner with Italy’s NTC to market a portfolio of ophthalmic brands in the MENA region. At the same time, the German generics giant has agreed a distribution deal for the Czech Republic with Latvia’s Kalceks.